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Abstract
Objectives:  To  evaluate  the  possible  effects  of  the  introduction  of  the  pneumococcal  conjugate
10-valent  vaccine  schedule  in  the  state  of  Parana  on  pneumococcal  meningitis  cases  and  to
assess the  distribution  of  serotypes  among  cases.
Method:  Cross-sectional  study  with  retrospective  data  collection  of  cases  of  pneumococcal
meningitis  in  the  state  of  Paraná  reported  to  Sistema  de  Informac¸ão  de  Agravos  de  Notiﬁcac¸ão
(SINAN),  from  1998  to  2011.  A  total  of  1,339  cases  of  pneumococcal  meningitis  were  analyzed;
1,205 cases  from  the  pre-vaccine  period  (1998-2009)  were  compared  to  134  cases  from  the
post-vaccine  period  (2010-2011).  Descriptive  and  comparative  statistical  analyses  (chi-squared
test and  prevalence  ratio)  were  performed  using  JMP  5.1.2  statistical  software  (JMP  Statistical
Discovery,  North  Carolina,  USA)  and  EPI  INFO  6  (Centers  for  Disease  Control  and  Prevention,
Georgia,  EUA).
Results:  There  was  a  signiﬁcant  reduction  in  the  mean  rates  of  incidence  and  mortality  in  the
general population.  The  analysis  of  cases  in  the  pre-  and  post-vaccination  periods  in  the  age
groups covered  by  vaccination  (younger  than  2  years)  showed  signiﬁcant  reductions  in  incidence
rates (6.01  cases/100,000  to  2.49  cases/100,000  individuals)  and  mortality  (1.85  cases/100,000
population  to  0.47  cases/100,000  population),  while  the  mean  lethality  rate  did  not  change
signiﬁcantly.  There  was  a  signiﬁcant  reduction  in  cases  whose  serotypes  are  included  in  the
vaccine  (80.7%  to  53.3%).
Conclusion:  Even  after  a  short  time  of  use,  the  10-valent  pneumococcal  conjugate  vaccine
has already  had  a  signiﬁcant  impact  in  reducing  the  incidence  and  mortality  of  meningitis
 Please cite this article as: Hirose TE, Maluf EM, Rodrigues CO. Pneumococcal meningitis: epidemiological proﬁle pre- and post-introduction
f the pneumococcal 10-valent conjugate vaccine. J Pediatr (Rio J). 2015;91:130--5.
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cases  among  infants,  as  well  as  the  reduction  of  cases  whose  serotypes  are  included  in  the
vaccine.
© 2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Resumo
Objetivos:  Avaliar  os  possíveis  efeitos  da  introduc¸ão  da  vacina  pneumocócica  conjugada  10
valente no  calendário  vacinal  no  Paraná  sobre  os  casos  de  meningite  pneumocócica;  avaliar  a
distribuic¸ão dos  sorotipos  dentre  os  casos.
Método:  Estudo  observacional,  transversal,  com  coleta  de  dados  retrospectiva  dos  casos  de
meningite  pneumocócica  no  Estado  do  Paraná,  notiﬁcados  ao  SINAN,  no  período  de  1998  a
2011. Foram  analisados  1339  casos  de  meningite  pneumocócica  e  comparados  os  1205  casos  do
período pré-vacina  (1998  a  2009)  com  os  134  do  período  pós-vacina  (2010  a  2011).  A  análise
estatística descritiva  e  comparativa  (teste  qui-quadrado  e  razão  de  prevalência)  foi  realizada
no software  de  estatística  JMP  5.1.2  (JMP  Statistical  Discovery,  Carolina  do  Norte,  EUA)  e  no
Programa  EPI  INFO  6.
Resultados:  Observou-se  reduc¸ão  signiﬁcativa  das  taxas  médias  de  incidência  e  mortalidade
na populac¸ão  geral.  A  análise  dos  casos  nos  períodos  pré  e  pós-vacina  nas  faixas  etárias
contempladas  pela  vacinac¸ão  (menores  de  2  anos)  mostrou  reduc¸ões  signiﬁcativas  das  taxas
de incidência  (6,01  casos/100.000  para  2,49  casos/100.000  habitantes),  mortalidade  (1,85
casos/100.000  habitantes  para  0,47  casos/100.000  habitantes),  enquanto  que  a  letalidade
média não  apresentou  variac¸ão  signiﬁcativa.  Houve  reduc¸ão  signiﬁcativa  dos  casos  cujos  soroti-
pos estão  incluídos  na  vacina  (80,7%  para  53,3%).
Conclusão:  Mesmo  com  um  tempo  reduzido  de  uso,  a  vacina  pneumocócica  conjugada  10
valente já  apresentou  um  impacto  relevante  na  diminuic¸ão  dos  coeﬁcientes  de  incidência  e  mor-
talidade dos  casos  de  meningite  entre  os  lactentes,  além  de  reduc¸ão  de  casos  cujos  sorotipos
estão incluídos  na  vacina.
© 2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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Streptococcus  pneumoniae  (pneumococcus)  can  be  found
in  the  nasopharynx  and  oropharynx  mucosa  of  healthy
humans,  and  is  important  due  to  its  morbidity  and  mortality
related  to  diseases  such  as  meningitis,  pneumonia,  and  sep-
ticemia,  among  others.1 In  Brazil,  it  is  the  second-leading
causative  agent  of  bacterial  meningitis,  following  Neisseria
meningitidis.2
Pneumococcal  disease  prevention  is  primarily  based  on
active  immunization.  A  total  of  93  pneumococcus  serotypes3
have  been  identiﬁed,  according  to  the  antigenicity  and
immunogenicity  of  the  polysaccharide  capsule,  the  main
bacterial  virulence  factor.  The  polysaccharide  antigens
induce  a  serotype-speciﬁc  immunological  response,  which
is  very  useful  for  the  composition  of  pneumococcal  vac-
cines.  The  23-valent  vaccine  consists  of  puriﬁed  capsular
polysaccharides  of  23  serotypes  of  Streptococcus  pneumo-
niae,  produces  thymus-independent  immune  response,  and
is  therefore  indicated  only  for  children  older  than  2  years  of
age.  When  the  polysaccharides  are  individually  conjugated
to  protein  carriers,  there  is  immunogenicity  improvement,
as  they  are  capable  of  triggering  the  immune  memory
response  (thymus-dependent)  and  can  be  administered  to
children  younger  than  2  years  of  age,  the  main  age  group
affected  by  invasive  pneumococcal  disease.1,4,5
r
b
o
wThe  pneumococcal  conjugate  vaccines  released  by  reg-
latory  agencies  and  currently  marketed  in  Brazil  are  the
0-valent  and  13-valent,  which  protect  against  ten  and  13
neumococcal  serotypes,  respectively.  The  10-valent  pneu-
ococcal  conjugate  vaccine  became  part  of  the  National
mmunization  Program  (NIP)  schedule  from  2010  for  chil-
ren  younger  than  24  months.  The  23-valent  pneumococcal
olysaccharide  vaccine  is  available  at  the  Special  Immuno-
iological  Reference  Centers  (Centros  de  Referências  de
munobiológicos  Especiais--CRIE)  to  patients  older  than  2
ears  of  age  considered  at  risk  for  invasive  pneumococcal
isease,  and  institutionalized  elderly  patients  older  than  60
ears.6
The  objective  of  this  study  was  to  evaluate  the  effect  of
he  introduction  of  the  10-valent  pneumococcal  conjugate
accine  into  the  NIP  vaccination  schedule  on  the  epidemio-
ogical  indicators  and  serotypes  of  pneumococcal  meningitis
n  the  state  of  Paraná,  Brazil.
ethods
his  was  an  observational,  cross-sectional  study  with  ret-
ospective  data  collection  of  cases  of  meningitis  caused
y  Streptococcus  pneumoniae, demonstrated  through  lab-
ratory  tests,  which  occurred  in  the  state  of  Paraná  and
ere  notiﬁed  to  the  Notiﬁable  Diseases  Information  System
1 Hirose  TE  et  al.
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Table  1  Distribution  of  cases  of  pneumococcal  meningitis
in the  periods  pre-  (1998-2009)  and  post-vaccination  (2010-
2011),  according  to  age  range.  Paraná,  1998-2011.
PRE-VACCINE POST-VACCINE
AGE  RANGE  n  %  n  %
<  1  year  314  26.1  16  11.9
1-4 years  156  12.9  20  14.9
5-9 years  102  8.5  15  11.2
10-14 years  86  7.1  9  6.7
≥ 15  years  543  45.1  74  55.2
Total 1201  100.0  134  100.0
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Sistema  de  Informac¸ão  de  Agravos  de  Notiﬁcac¸ão--SINAN),
rom  January  of  1998  to  December  of  2011.
The  analysis  of  cases  of  pneumococcal  meningitis  was
erformed  by  comparing  the  periods  according  to  the  intro-
uction  of  10-valent  pneumococcal  conjugate  vaccine  in  the
IP.  The  pre-vaccine  period  included  the  years  1998  to  2009,
nd  the  post-vaccine  period,  the  years  2010  and  2011.
The  indicators  used  for  the  analysis  of  cases  over  the
ears,  or  in  the  pre-  and  post-vaccine  periods,  based
n  population  data  from  the  Brazilian  Institute  of  Geog-
aphy  and  Statistics  (Instituto  Brasileiro  de  Geograﬁa  e
statística--IBGE)  were  as  follows:
 Mean  incidence  rate:  (mean  number  of  meningitis  cases
in  the  period/mean  population  of  the  period)  ×  100,000
 Mean  mortality  rate:  (mean  number  of  deaths  due  to
pneumococcal  meningitis  in  the  period/mean  population
of  the  period)  ×  100,000.
 Mean  lethality:  (mean  number  of  deaths  by  pneumococ-
cal  meningitis  in  the  period/mean  number  of  cases  of
pneumococcal  meningitis  in  the  period)  ×  100.
The  term  ‘‘vaccination  coverage’’  was  used  for  the  fre-
uency  of  the  serotypes  available  in  the  conjugate  vaccines
f  the  studied  sample.
Data  were  recorded  in  a  Microsoft  Excel® 2010  (Microsoft,
ew  York,  USA)  spreadsheet,  veriﬁed,  and  then  exported  to
MP  Statistical  Discovery  Software  5.1.2  (JMP  Statistical  Dis-
overy,  North  Carolina,  USA)  and  EPI  INFO  6  (Centers  for
isease  Control  and  Prevention,  Georgia,  USA).  The  esti-
ate  of  the  difference  between  categorical  variables  was
erformed  by  chi-squared  test,  with  a  minimum  signiﬁcance
evel  of  5%.  The  prevalence  ratio  was  used  in  the  comparison
f  cases  in  children  younger  than  1  year  between  the  pre-
nd  post-vaccine  periods,  with  a  conﬁdence  interval  of  95%.
The  study  was  approved  by  the  Research  Ethics  Com-
ittee  of  the  Department  of  Health  of  the  State  of
araná/Hospital  do  Trabalhador,  on  August  26,  2010,  Case
o.  218/2010.
esults
etween  January  of  1998  and  December  of  2011,  1,354  cases
f  pneumococcal  meningitis  were  reported  to  SINAN  in  the
tate  of  Paraná.  Of  this  population,  15  cases  were  excluded
ue  to  inconsistency  of  information  and  duplicate  notiﬁca-
ions,  totaling  1,339  cases,  with  1,205  in  the  pre-vaccine
nd  134  in  the  post-vaccine  period.
The  distribution  of  cases  according  to  age  range  in  both
eriods  is  shown  in  Table  1.  When  analyzing  the  pre-vaccine
nd  post-vaccine  periods,  a  54%  reduction  can  be  observed
n  the  frequency  of  cases  in  the  age  group  <  1  year  (26.1%
o  11.9%,  respectively).  The  prevalence  ratio  among  cases
f  pneumococcal  meningitis  in  children  younger  than  1  year
etween  the  pre-  and  post-vaccine  periods  was  2.68  (95%
I:  1.62  to  4.44,  p  <  0.01).
1.  Evaluation  of  epidemiological  indicators  in  the  pre  and
ost-vaccine  periods:
When  comparing  the  epidemiological  indicators  between
he  two  studied  periods  in  the  general  population,  there
as  a  signiﬁcant  decrease.  The  mean  incidence  rate
v
b
t
nCases/year  100  67
Obs: Four cases had no data on age in the pre-vaccine period.
ecreased  by  36.0%  (1.00  cases/100,000  inhabitants  to  0.64
ases/100,000  inhabitants;  p  <  0.001)  and  the  mean  mor-
ality  rate  decreased  by  65.5%,  from  0.29  cases/100,000
nhabitants  to  0.10  cases/100,000  inhabitants  (p  <  0.001).
When  analyzing  the  proﬁle  indicators  between  pre-and
ost-vaccine  periods,  speciﬁcally  in  the  population  of  chil-
ren  younger  than  2  years,  there  were  signiﬁcant  reductions
n  mean  incidence  and  mortality  rates  (Table  2).  The  mean
ncidence  rate  decreased  by  59.9%  (6.21  cases/100,000  to
.49  cases/100,000  inhabitants;  p  <  0.01),  and  the  mean
ortality  rate  decreased  by  75.5%  (1.92  deaths/100,000
o  0.47  deaths/100,000;  p  <  0.01).  Similar  results  were
btained  in  the  analysis  of  the  age  range  younger  than  1
ear  and  between  1  and  2  years.  Although  lethality  rates
lso  decreased  between  the  two  periods,  the  differences
ere  not  statistically  signiﬁcant.
2.  Distribution  of  serotypes  identiﬁed  in  the  pre-  and
ost-vaccine  periods:
In  the  pre-vaccine  period,  46.3%  (558/1205)  of  the  cases
ere  serotyped.  Of  these,  58.1%  corresponded  to  cases  of
hich  pneumococcus  serotype  was  included  in  the  10-valent
onjugate  vaccine  (1,  4,  5,  6B,  7F,  9  V,  14,  18  C,  19F,  23F).
n  the  post-vaccine  period,  45.5%  (61/134)  of  the  cases
ere  serotyped,  of  which  47.5%  were  caused  by  serotypes
ncluded  in  the  vaccine.  When  the  possible  cross-protection
etween  serotypes  6A  and  6B  is  considered,  in  the  pre-
nd  post-vaccine  periods,  the  identiﬁcation  of  62.2%  and
2.5%  of  the  serotypes  included  in  the  10-valent  vaccine  are
bserved,  respectively.
When  analyzing  the  most  frequent  serotypes  between
he  periods  in  the  general  population,  an  increase  in  the
requency  of  cases  with  serotype  3,  10A,  and  4  in  the  post-
accination  period  is  observed,  with  the  ﬁrst  two  serotypes
ot  included  in  the  10-valent  conjugate  vaccine.
3.  Distribution  of  serotypes  in  the  age  range  younger  than
 years:
The analysis  of  serotyped  cases  in  the  age  group  younger
han  2  years  (covered  by  the  vaccine  distributed  by  the
IP)  showed  that  of  the  202  cases  analyzed  (187  in  the  pre-
accine  and  15  in  the  post-vaccine  period),  the  percentage
f  serotyped  cases  caused  by  serotypes  included  in  the  10-
alent  conjugate  vaccine  had  decreased  from  75.9%  to  46.7%
etween  the  pre-  and  post-vaccine  periods.  Considering  only
he  age  range  of  12-23  months,  the  decrease  was  more  sig-
iﬁcant  (from  73.9%  to  20%).  The  comparison  between  the
Pneumococcal  meningitis:  epidemiological  proﬁle  pre  and  post-vaccine  133
Table  2  Epidemiological  indicators  for  pneumococcal  meningitis  in  children  younger  than  2  years.  Paraná,  1998-2011.
COEFFICIENTS  PRE-VACCINE  POST-VACCINE  p
<  1  year
Mean  incidence  rate  (cases/100,000) 14.85 5.53  <  0.001
Mean mortality  rate  (deaths/100,000)  4.59  1.04  <  0.001
Mean lethality  rate  (%)  30.89  18.8  0.45
1-2 years
Mean  incidence  rate  (cases/100,000)  1.86  0.9  <  0.001
Mean mortality  rate  (deaths/100,000)  0.57  0.18  <  0.001
Mean lethality  rate  (%)  30.77  20.00  0.99
< 2  years
Mean  incidence  rate  (cases/100,000) 6.21  2.49  <  0.001
Mean mortality  rate  (deaths/100,000)  1.92  0.47  <  0.001
Mean lethality  rate  (%)  30.87  
Table  3  Coverage  of  the  10-valent  pneumococcal  conju-
gate vaccine  in  the  pre-  and  post-vaccine  periods  according
to age.
PRE-VACCINE  POST-VACCINE  p
<  12  MONTHS
10-valent  76.6%  60.0%  0.42
Cross-protection  80.90%  60.0%  0.14
12-23 MONTHS
10-valent  73.9%  20.0%  0.05
Cross-protection  80.4%  40.0%  0.24
< 24  MONTHS
10-valent  75.9%  46.7%  0.03
Cross-protection  80.7%  53.3%  0.03
2
m
w
h
v
(
p
8
i
i
c
t
v
t
R
s
i
t
a
i
i
o
b
w
v
d
n
s
t
c
t
v
a
p
8
aObs: Cross-protection with serotype 6 A.
pre-  and  post-vaccine  periods  in  children  younger  than  2
years,  with  the  expansion  of  cross-protection  of  serotype
6A,  shows  a  signiﬁcant  decrease  in  cases  of  which  serotypes
are  included  in  the  vaccine  (from  80.7%  to  53.3%,  p  =  0.030;
Table  3).
Discussion
The  analysis  of  the  effects  of  the  introduction  of  the  10-
valent  conjugate  vaccine  in  the  NIP  in  the  Brazil  must  be
carefully  considered.  The  10-valent  pneumococcal  conju-
gate  vaccine  was  introduced  into  the  routine  immunization
program  in  Brazil  from  March  to  September  of  2010.7
In  the  present  study,  when  comparing  the  pre-vaccine
(1998-2009)  with  the  post-vaccine  period  (2010  and  2011),
and  even  including  the  year  2010,  which  was  a  transition
period  when  municipalities  were  progressively  implemen-
ting  pneumococcal  vaccine  at  the  basic  health  units,  a
reduction  of  54%  in  cases  of  meningitis  in  children  younger
than  1  year  was  found,  with  the  highest  prevalence  of  cases
in  this  age  group  in  the  pre-vaccine  period.  When  analyzing
the  general  population,  the  incidence  rates  and  the  mean
mortality  rates  decreased  by  36.0%  and  65.5%,  respectively.
For  the  age  group  covered  by  the  vaccine,  i.e.,  younger  than
c
s
l19.05  0.25
 years,  signiﬁcant  reductions  in  the  mean  incidence  and
ortality  rates  (reduction  of  59.9%  and  75.5%,  respectively)
ere  also  observed.
Since  the  Kaiser  Permanent  Study  Center,8 studies
ave  shown  the  beneﬁts  of  using  conjugate  pneumococcal
accines.9,10
The  use  of  the  7-valent  pneumococcal  conjugate  vaccine
no  longer  marketed)  showed  97%  efﬁcacy  against  invasive
neumococcal  diseases  caused  by  vaccine  serotypes  and
9%  against  invasive  pneumococcal  diseases  in  general.  The
mpact  of  this  vaccine  was  demonstrated  by  the  reduction  of
nvasive  diseases,  from  79%  to  100%,  and  in  cases  of  medical
onsultations  for  acute  otitis  media,  with  an  impact  of  13%
o  43%.11 Regarding  the  10-valent  pneumococcal  conjugate
accine,  Afonso  et  al.  found  signiﬁcant  reductions  in  hospi-
alizations  for  pneumonia  in  Belo  Horizonte,  Curitiba,  and
ecife,  after  its  introduction  in  the  Brazilian  immunization
chedule.12 This  vaccine  also  showed  to  be  effective  in  stud-
es  performed  in  Finland13 and  Quebec,14 with  reductions  in
he  incidence  rates  of  invasive  pneumococcal  diseases.
Although  the  post-vaccine  period  in  Brazil  still  comprises
 short  time  period,  with  a  three-dose  vaccine  coverage
n  the  ﬁrst  year  of  life  of  35.36%  in  2010,  reaching  94.19%
n  2011,15 a  reduction  in  epidemiological  indicators  can  be
bserved,  which  is  in  agreement  with  studies  that  showed
eneﬁts  with  the  use  of  pneumococcal  conjugate  vaccines
ithin  15  months  after  its  introduction.14 The  impact  of  the
accine  use  and  indirect  beneﬁts  of  the  herd  effect,  i.e.,
ecreased  cases  in  unvaccinated  individuals  by  reducing
asopharyngeal  colonization  and  transmission  of  vaccine
erotypes  by  vaccinated  children16 would  be  too  early  at
his  stage  of  the  analysis.  It  is  expected  that  data  will  be
ompatible  with  those  found  in  effectiveness  studies  after
he  introduction  of  the  7-valent  pneumococcal  conjugate
accine,  in  which  the  indirect  effects  were  responsible  for
 19%  to  62%  reduction  in  the  overall  incidence  of  invasive
neumococcal  diseases  in  individuals  aged  >  18  years,  and
1%  to  92%  of  cases  related  to  vaccine  serotypes  in  the  same
ge  group.11When  the  main  pneumococcal  serotypes  identiﬁed  in
ases  of  meningitis  in  this  research  were  compared  with
erotypes  included  in  the  10-valent  conjugate  vaccine,  a
ower  rate  was  observed  (58.1%  pre-vaccine)  in  relation  to
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ther  reported  studies.  However,  considering  the  possible
ross-protection  between  serotypes  6A  and  6B,  there  would
e  an  identiﬁcation  of  62.2%  in  the  pre-vaccine  period.
Rates  found  in  Brazil  were  77.6%  for  the  10-valent  conju-
ate  vaccine  and  86%  for  the  13-valent  conjugate  vaccine
or  invasive  pneumococcal  diseases;17,18 data  from  Africa
how  rates  of  70%  to  84%  for  the  10-valent  conjugate  vaccine
nd  from  79%  to  88%  for  the  13-valent  conjugate  vaccine.19
or  meningitis,  the  coverage  of  the  10-valent  and  13-valent
onjugate  vaccines  would  be  82.8%  and  94.2%,  respectively.2
In  this  study,  when  comparing  the  periods  before  and
fter  the  introduction  of  the  10-valent  conjugate  vaccine
n  the  Brazilian  NIP,  a  signiﬁcant  reduction  was  observed  in
ates  of  serotypes  included  in  the  vaccine  as  the  cause  of  dis-
ases  in  the  age  range  <  2  years  (from  80.7%  to  53.3%),  which
ould  be  explained  by  the  routine  use  of  this  immunobiolog-
cal  agent.
When  making  a  projection,  comparing  the  coverage  of
neumococcal  conjugate  vaccines  available  in  Brazil,  there
s  better  coverage  (serotypes  included  in  the  vaccines  coin-
ident  with  the  isolates  in  the  state)  with  the  13-valent
accine,  when  compared  to  the  10-valent,  both  in  the
re-vaccine  (69.2%  and  58.1%,  respectively,  p  <  0.01)  and
he  post-vaccine  period  (68.9%  and  47.5%,  respectively,
 =  0.017).  If  the  10-valent  vaccine  coverage  were  extended
ith  the  cross-protection  of  serotype  6A,  this  difference
ould  not  be  maintained  in  the  post-vaccine  period  (13-
alent:  68.9%  and  10-valent:  52.5%,  p  =  0.064),  but  rather,
nly  in  the  pre-vaccine  period  (13-valent:  69.2%  and  10-
alent:  62.2%,  p  =  0.014).
The  effect  of  serotype  replacement,  i.e.,  increase  in
ases  by  serotypes  not  included  in  the  conjugate  vaccines
hrough  a  reduction  in  the  circulation  of  vaccine  serotypes
n  a  vaccinated  population,20 appears  to  be  premature,  in
ddition  to  the  fact  that  ﬂuctuations  in  the  frequency  of  the
erotypes  can  occur  without  the  need  for  selective  pressure
f  vaccines.21 In  the  present  study,  an  increase  in  the  num-
er  of  cases  in  the  post-vaccine  period  was  observed  due  to
erotypes  3  and  10A,  not  included  in  the  10-valent  conjugate
accine.  In  Europe  and  the  United  States,  after  using  the
-valent  pneumococcal  conjugate  vaccine,  the  main  non-
accine  serotypes  found  in  invasive  pneumococcal  diseases
ere  1,  3,  7F,  15,  19A,  27F,  and  33F.22
The  analysis  of  cases  of  pneumococcal  meningitis  in  the
re-  and  post-vaccine  periods  showed  a  reduction  of  cases
n  the  age  range  <  1  year,  signiﬁcant  reductions  in  inci-
ence  and  overall  mortality  coefﬁcients,  and  of  the  same
oefﬁcients  in  the  age  groups  covered  by  the  vaccine.  The
overage  of  pneumococcal  vaccines  for  meningitis  cases  was
ower  than  that  described  in  the  literature,  but  with  a  reduc-
ion  of  the  vaccine  serotypes  in  the  post-vaccine  period.
One  limitation  of  this  study  was  the  source  of  data  for
nalysis,  which  is  based  on  notiﬁcation  data.  Although  noti-
cation  of  meningitis  is  compulsory  in  Brazil,  the  lack  of
ome  information,  the  divergence  of  data,  and  the  lack
f  proper  completion  of  forms  at  times  prevented  a  more
omplete  analysis  of  the  available  data,  information  that
ould  not  be  included  in  this  research.  Nevertheless,  the
evelopment  of  new  studies  that  follow  the  scenario  of
nvasive  pneumococcal  diseases  in  the  state  (not  only  of
eningitis),  the  effects  of  the  introduction  of  pneumococ-
al  conjugate  vaccine  into  the  NIP,  and  the  maintenance  of
1Hirose  TE  et  al.
urveillance  on  serotypes  circulating  in  the  population  are
ncouraged.
Permanent  surveillance  of  cases  of  pneumococcal  menin-
itis  and  the  most  prevalent  serotypes  allows  the  choice  of
onjugate  vaccines  that  are  best  adapted  to  the  geographi-
al  region  and  its  population.
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